These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31279154)

  • 1. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
    Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
    Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
    Minichmayr IK; Friberg LE
    Int J Antimicrob Agents; 2024 Aug; 64(2):107236. PubMed ID: 38851463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection.
    Kongthavonsakul K; Lucksiri A; Eakanunkul S; Roongjang S; Issaranggoon Na Ayuthaya S; Oberdorfer P
    Int J Antimicrob Agents; 2016 Aug; 48(2):151-7. PubMed ID: 27345269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients.
    Tsumura R; Ikawa K; Morikawa N; Ikeda K; Shibukawa M; Iida K; Kurisu K
    J Chemother; 2008 Oct; 20(5):615-21. PubMed ID: 19028626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid population pharmacokinetic modeling and simulation of meropenem after intravenous and intrathecal administration in postoperative neurosurgical patients.
    Li X; Wang X; Wu Y; Sun S; Chen K; Lu Y; Wang Q; Zhao Z
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):386-392. PubMed ID: 30638947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetic/pharmacodynamic parameters, in the treatment of bacterial meningitis.
    Morikawa Y; Kitazato M; Morita T; Mizunaga S; Mitsuyama J
    J Infect Chemother; 2009 Aug; 15(4):233-8. PubMed ID: 19688242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic analysis of meropenem, by Monte Carlo simulation, in both plasma and cerebrospinal fluid in patients with cerebral hemorrhage after external ventricular drainage
.
    Kong L; Xu H; Wu C; Kong X; Yu M; Shi Q; Wu X
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):50-56. PubMed ID: 31670654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Paediatr Drugs; 2006; 8(2):131-8. PubMed ID: 16608373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
    Ohata Y; Tomita Y; Nakayama M; Kozuki T; Sunakawa K; Tanigawara Y
    Drug Metab Pharmacokinet; 2011; 26(5):523-31. PubMed ID: 21747200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.
    Lu C; Zhang Y; Chen M; Zhong P; Chen Y; Yu J; Wu X; Wu J; Zhang J
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6619-6625. PubMed ID: 27572392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.